Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Abstract

Purpose. We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in the management of relevant toxicities emerging in patients with novel coronavirus pneumonia (COVID-19). Methods. Reports to the FAERS from 1 January 2004 to 8 March 2020 were analyzed. The proportion of report ratio (PRR), reporting odds ratio (ROR), and Bayesian confidence interval progressive neural network (BCPNN) method were used to detect the safety signals. Results. A total of 55 safety signals were detected from the top 250 adverse event reactions in 2200 reports, but 19 signals were not included in the drug labels. All the detected adverse event reactions were associated with 13 System Organ Classes (SOC), such as gastrointestinal, blood and lymph, hepatobiliary, endocrine, and various nervous systems. The most frequent adverse events were analyzed, and the results showed that females were more likely to suffer from anemia, vomiting, neutropenia, diarrhea, and insomnia. Conclusion. The ADE (adverse drug event) signal detection based on FAERS is helpful to clarify the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy; clinicians should pay attention to the adverse reactions of gastrointestinal and blood systems, closely monitor the fluctuations of the platelet count, and carry out necessary mental health interventions to avoid serious adverse events.

The application of artificial intelligence and data integration in COVID-19 studies: a scoping review

“…In the lone study that integrated heterogeneous data for modeling, Abdalla et al integrated 43 sociodemographic variables from multiple sources (eg, Census Bureau, US Department of Agriculture, Centers for Disease Control and Prevention) and built elastic net models to examine how sociodemographics impacted county-level social distancing ( Table 4 ). 130 Of the remaining studies, 1 used ANN to perform a drive-through mass vaccination simulation, 138 while the other 4 used NLP methods and tools on various research topics, including cross-lingual clinical deidentification in electronic health records (EHRs), 139 dream reports analysis, 140 drug safety analysis by mining the FDA adverse event system, 141 COVID-19 clinical concept (signs and symptoms) identification, and normalization in EHRs. 142 …”

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

“…Favipiravir has shown side effects such as QTC prolongation, hyperuricemia, abnormalities in liver enzymes, elevation of uric acid, total bilirubin, and liver enzymes, along with gastrointestinal disorders in clinical trials. Conversely, no adverse events were reported in the azvudine group in a clinical trial (Ren et al, 2020;Shan et al, 2020;Wu et al, 2022;Alsuhaibani et al, 2023;Batool et al, 2023). In addition,…”

The clinical characteristics and treatment approaches of COVID-19: a concise review

“…It can be use for hepatitis C virus infection treatment. 104 This drug in combination with interferon was an suggested treatment Pharmaceutical Sciences, 2021, 27(Suppl 1), S50-S67 | S58…”